-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
2017
-
Ravi Salgia, MD, PhD
Ravi Salgia, MD, PhD, was awarded the IACA Award for Outstanding Contributions to Oncology by the Indo-American Cancer Association (IACA). This award is given to medical oncologists and researchers who […]
-
Mental Health Really Matters: Lung Cancer Diagnosis Has the Greatest Risk of Suicide among Cancer Patients in USA – SEER Database Analysis
By Mohamed Rahouma, MD, Mohamed Kamel, MD, and Jeffrey L. Port, MD A cancer diagnosis can be overwhelming, especially if someone has limited social support. Previous international reports have indicated […]
-
Solange Peters, MD, PhD
Solange Peters, MD, PhD, was elected President for 2020-2021 of the European Society for Medical Oncology (ESMO). Professor Peters is Head of the Medical Oncology Service, Chair of Thoracic Oncology, […]
-
Naiyer A. Rizvi, MD
Naiyer A. Rizvi, MD, was named to the ARMO BioSciences, Inc., Board of Directors, Redwood City, US. Dr. Rizvi is Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Division […]
-
David R. Gandara, MD
David R. Gandara, MD, was honored as the lung cancer “Giant of Cancer Care” in the 2017 Giants of Cancer Care® recognition program by OncLive. Awardees are selected by their […]
-
Promise of Smoke-Free Future Falls Short
Editor’s Note: IASLC Lung Cancer News is pleased to publish this article as part of its continuing focus on the expansion of “combustible tobacco” (cigarettes) to include non-combustible products and […]
-
Roman V. Petrov, MD, PhD
Roman V. Petrov, MD, PhD, has been appointed Assistant Professor, Department of Surgical Oncology, Fox Chase Cancer Center; and Assistant Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine, […]
-
Gideon M. Blumenthal, MD
Gideon M. Blumenthal, MD was named Acting Deputy Director, Office of Hematology & Oncology Products, US Food and Drug Administration, Silver Spring, US. Prior to this appointment, Dr. Blumenthal was […]
-
Q&A with Alice Shaw, MD, PhD
Based on global ALEX, has crizotinib been relegated to the therapeutic scrapheap when it comes to patients with ALK rearrangements? Or does it retain some role? The global ALEX study, […]
-
Q&A with Benjamin Solomon, MBBS, PhD, FRACP
Please give us a global perspective on the results of global ALEX. Will alectinib definitively displace crizotinib or ceritinib as the first-line treatment for ALK-rearranged non-small cell lung cancer (NSCLC)? […]